Icotrokinra

Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis. It is a cyclic peptide that functions as a selective interleukin 23 (IL-23) receptor antagonist. It is a synthetic peptide that binds selectively to the IL-23 receptor (IL-23R) with high affinity and competitively antagonizes the binding of IL-23.

It is an immunosuppressant and interleukin inhibitor. It is being developed by Johnson & Johnson. Icotrokinra was approved for medical use in the United States in March 2026.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378710068 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

17 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.